FREE CONSULTATION: 866-425-8902

Xarelto: Quick Facts About Xarelto Litigation

Xarelto (Rivaroxaban) Linked To Deaths And Serious Injury

You will likely have seen Xarelto lawsuit TV commercials and several Facebook advertisements lately about Xarelto lawsuits. You may have suffered a serious injury, or you may have lost a loved one to a stroke, heart attack, brain hemorrhage, internal bleed, or pulmonary embolism. If you or your loved one took Xarelto, it may have been the cause, and you and your family may be entitled to compensation.

The FDA has reported thousands of “adverse events” where serious injuries from internal bleeding have occurred, and have linked it to Xarelto.

12 Facts About The Xarelto Litigation

  1. In 2011, the Food & Drug Administration approved Xarelto (rivaroxaban) for preventing blood clots and deep vein thrombosis in patients undergoing knee and hip replacements, atrial fibrillation, and for general use in reducing the recurrence of blood clots, and stent thrombosis in patients with acute coronary syndrome.
  2. The manufacturers of Xarelto (rivaroxaban) are Bayer AG and Johnson & Johnson.
  3. The drug was first introduced in the United States in 2011.
  4. There is no known reversal agent or antidote for Xarelto and dialysis is not a solution for flushing the drug from your system to enable blood clotting/coagulation.
  5. A Phase III study showed that 73% of study participants (a total of 16,041 individuals), who took Xarelto suffered from an adverse side effect such as internal bleeding or anemia.
  6. In August 2013, the FDA issued a warning that premature discontinuance of Xarelto leads to a higher risk of blood clots.
  7. In 2013, the manufacturers of Xarelto profited with sales of $1.4 billion
  8. The first lawsuit filed alleging Xarelto was the cause of a patients death because of uncontrollable bleeding occurred in January 2014.
  9. Most lawsuits allege that Xarelto caused uncontrollable internal bleeding resulting in death or serious injury.
  10. Common reported injuries are: gastrointestinal bleeding, brain hemorrhages, internal bleeding, rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma, stroke, and heart attacks.
  11. Federally filed Xarelto lawsuits have been centralized by the formation of a Multidistrict Litigation panel in New Orleans, Louisiana in December 2014.
  12. Xarelto lawsuits filed in the commonwealth of Pennsylvania have been consolidated to a mass tort program for efficient management of the litigation.